Showing posts with label Biopharma. Show all posts
Showing posts with label Biopharma. Show all posts

Thursday, October 20, 2016

FDA/CMS: New Administration, New Challenges?

Knect365 FDA/CMS Summit, photo on-site
photo credit: @KimTweetsDC

For over 20 years we have been working hard on delivering you with first-hand insights into one of the most heavily-regulated industries in the world.

With recent debates over drug pricing, the FDA is faced with some challenges over regulation policies to ensure the healthy balance of big pharma companies on the market.


Here are the main three questions that are bugging the minds of the Top Biopharma Executives today:


• What does the future hold for the Affordable Care Act and health reform in the post-Obama landscape?
• What is the state of biosimilars in the US, and how these medicines may impact the cost curve for biologics as more reach the market and uptake becomes measurable?
[read an excerpt from the panel discussion with experts from Mylan, Pfizer and Momenta Pharmaceuticals “Biosimilars are here. Now what?”.]
• Transparency around pricing.

Do these topics keep you up all night as well?

Be the first one to learn the updates directly from CDER and CMS right in the heart of DC, the political epicenter of the United States at the 11th Annual FDA/CMS Summit.


Some of the themes to be discussed at the Summit include:


• An overview of regulatory and policy news;
• Regulatory & reimbursement expertise from KaloBios Pharmaceuticals Inc., FDA, REGENXBIO, Aimed Alliance, Acorda Therapeutics, Beth Israel Deaconess Medical Center, and many others;
• The state of biosimilars and revisions to BSUFA;
• Drug Development Innovation including regulatory strategies of pandemics such as Ebola and Zika.

For the full range of topics download the brochure here.

Join an open dialog over the industry issues with other health care professionals from the FDA and CMS regulatory agencies, including Janet Woodcok, Gerald Dal Pan and John Jenkins at the FDA/CMS Summit, this December, 14 – 15th in Washington, DC.

As a valued member of our community you can register with a special discount of $100 OFF the current rate using this code: PFDA16SOCIAL.

Secure your spot and the best rate here.



Stay tuned:



Share this article with your social network, just click below to share now!


Tuesday, May 3, 2016

Preparing for future bioprocessing challenges with the Cellca CHO Expression Platform

Therapeutic protein development and production is a very technically challenging, time consuming and expensive endeavor.

What are some of the challenges? There are numerous critical decisions that must be made with regard to mammalian cell line choice (CHO, NS0, etc.), appropriate gene and marker expression systems, cell culture medium and feed optimization, clone selection and scale-up strategies. Biopharmaceutical developers should be careful to choose options which deliver the following:

• Maximum protein titer
• Scalability (5L – 1000L)
• Long-term Stability
• Cost effectiveness
• Shortened development timelines
• No burdensome IP concerns

Why is it important and critical to understand these challenges? There are considerable economic considerations to be made; one should maximize financial budgets by minimizing expenditures on equipment and technologies required for in-house development and characterization of the therapeutic protein. It’s important to make efficient and productive investments in R&D; technology and process development requires highly trained and expert staff. There are also commercial or market considerations which will affect return on investments; to maximize IP and patent life the therapeutic protein must be developed and commercialized as quickly as possible to gain maximum market share in a highly competitive environment. First to market is paramount for biosimilar developers.

How has the CRO industry responded? “Turn-key” cell line development and bioanalytical testing CROs are currently open for business and accessible for outsourcing nearly all upstream, downstream and biomolecular analytical activities. Sartorius Stedim Biotech offer the most comprehensive, scalable and unique bioprocess portfolio to support Biosimilar development and manufacturing. With Sartorius Stedim Biotechs’ recent acquisition of Cellca (cell line development) and BioOutsource (bioanalytical and biosafety testing), there is now established a fully functional, and integrated CRO uniquely positioned to support clients development programs across the entire product lifecycle.

The result of outsourcing biopharmaceutical development and production to experienced CROs will have major positive implications for shortening the time to commercialization at significantly reduced costs.

To learn more about the industry leading Cellca CLD platform which delivers stable, high titre clones, (95% of projects have delivered titres >3.0g/litre) in a proven scalable fed batch manufacturing process in a cost and time efficient manner please join our talk by Dr. Brian Wendelburg at IBC Cell Line Development & Engineering Conference, San Francisco, 14th June at 1.25pm.



Author Bio:


Dr. Brian Wendelburg received his Ph.D. in Molecular Biophysics from the Institute of Molecular Biophysics at Florida State University. He then completed his postdoctoral training at the University of North Carolina’s Lineberger Comprehensive Cancer Center. His professional career has involved diverse roles in sales and business development activities at leading Biotech companies such as Cepheid, Affymetrix and Miltenyi Biotec where he gained a strong technical background in genomics, proteomics and cell and gene therapy applications. He joined the Sartorius-Stedim Biotech team in the spring of 2016 and is currently Sr. Field Marketing Manager for the BioOutsource and Cellca divisions.


Share this article with your social network, just click below to share now!


Tuesday, April 5, 2016

Exclusive Interview with Dr. Bruce Riser, CEO, BLR-Bio, LLC



IBC's 18th Annual TIDES is the industry's #1 forum for oligonucleotide and peptide leaders to build successful partnerships and accelerate products from early discovery through late-stage development and commercialization. The TIDES team recently talked to Bruce L. Riser, Ph.D., CEO, BLR-Bio, LLC for an exclusive interview that delves into the topics he plans to discuss at the upcoming Oligonucleotide and Peptide Therapeutics event in Long Beach, CA.

What are the biggest challenges of bringing new agents with novel targets to the market?

BR: There are really two big challenges when bringing new agents with novel targets to the market. First, many investors and potential partners are not familiar with the target, or they do not have the comfort that exists with an established target. Second, there can be misperceptions in the scientific community and in the biopharmaceutical industry where an agent is associated with another type of development creating a negative halo. On the first challenge, it is easy to see a proven target and to line up, jumping on the bandwagon with others trying to either win the race to launch first or to attempt to find a niche in an already established area. The problem of course is that lining up with everyone else does not provide the opportunity to develop and launch a true breakthrough therapy that can change the treatment paradigms and have a breakthrough impact on peoples' lives. Instead, investors and companies that line up for the established target often find they are trailing others to the market and are never able to successfully establish themselves in the market. It really takes a visionary to see the potential of a new target and have the insight and strength to invest in it. The second challenge, dealing with miss-associations of a novel therapy with other developments can be truly vexing. Our peptides target the novel CCN signaling pathway, leveraging the unique qualities of CCN3 to target the control of ECM changes in response to injury, blocking fibrosis and creating an environment for re-establishment of complete tissue homeostasis. By creating peptide libraries and conducting diverse in vitro and in vivo screens we have identified specific regions with the CCN3 protein responsible for blocking single, or multiple, pathways to fibroblast and cancer growth, and fibrosis formation. Unlike other products such as antibodies directed against the pro-fibrotic CCN2, that appear to partially block a single pathway, our novel therapy regulates vs. simply blocking, thus allowing reestablishment of the body's healthy equilibrium.

With several peptide products in the pipeline in preclinical development and a wide range of possible disease applications, how have you selected your lead indication target(s)?

BR: Having several products covering a wide variety of diseases is great and choosing lead indications to pursue is a wonderful challenge to have. In reality, the two lead indications that we have chosen to pursue have as much to do with the research that we have done with my team as it does the extreme health care need. My long background in academia, clinical nephrology/public health, and pharmaceutical drug R&D has driven the way we do drug discovery at BLR Bio. First, working to clearly understand the pathways to disease before selecting a target, and trying not to get caught up by targets in vogue. Then, testing our peptides in multiple related diseases before moving into the clinic. Our pipeline was created out of our long-term interest in fibrosis and the extracellular matrix in biology and disease, particularly in renal fibrosis as a complication of diabetes an area of great medical need. This has led to the selection of diabetic nephropathy as a main target for one of our lead products. Since our target, and the peptide inhibitor of our target, are involved in many other forms of fibrosis and other disease involving the miss-regulation of matricellular signaling, this creates other exciting therapeutic indications down the road. These include NASH, IPF, MD, and scleroderma to name a few.

I began my career in cancer research, and we know now that the extracellular matrix and matricellular signaling proteins such as the CCNs are critical also in the formation and resolution of tumors. The pro-fibrotic CCNs, CCN2 and CCN4 in particular have been shown to be important for the establishment and likely invasion and metastases in numerous tumors. The opportunity to use CCN3-based therapy to, not only halt the cancer, but also to target the microenvironment is an exciting one. Our company is particularly excited about the potential in pancreatic cancer. We have an established relationship with thought leaders in the cancer field and are moving forward with development work, partnering with some of these world experts. To add to the excitement of the therapies, our company also is developing a diagnostic/theranostic based on the same technology platform. It holds the promise of either stand-alone or companion diagnostics for development.

What are the key advantages of peptide therapeutics over small molecules, antibodies and other protein therapeutics?

BR: As you know, peptide-based drugs are one of the most rapidly growing areas in therapeutic development. More than 100 peptide-based drugs are on the market with several effective in cancer treatment. There is good reason for this. In size, falling between small molecule drugs and "biologics", they have many of the benefits of both while shedding many of the deficiencies. For example, because of their small size they gain many delivery benefits over biologics. First, better penetration of tissue at the site of action. This is crucial in fibrotic disease and cancer where there is a very strong barrier to penetration. Second, it allows for many more delivery options, including oral formulation. The earlier assumption of poor metabolic stability of peptides has just not proven to be the case. Although there is often rapid clearance from circulation, the previous assumptions about required PK by classic definition has also proven to be not relevant, since a specific and sustained biological activity at the target receptor is characteristic of many peptides. Unlike small molecules they are based on sequences that have evolved to react with specific receptors and often at very low concentrations. This results in very low off target effects. Last, since they can be chemically synthesized the ease and cost to manufacture are more nearly like that of small molecules. The majority of approved peptides are in the 15 amino acids (aa) range or smaller, and they treat a broad range of diseases.

How do you see academia and industry collaborating in the future to advance promising peptide therapeutics into commercially viable products?

BR: First, we think that academia will play a significant role in the creation of new peptide-based therapies in the future. Since the last decade has seen a decline in the number of newly approved drugs from large pharma, and recently there has been a strong trend for these same companies to dramatically reduce their discovery effort, this creates a large opportunity for novel peptide therapies and academic-initiated translational research. This does not necessarily mean that the new paradigm will be that large strategic companies will license early stage assets directly from Universities. Rather, we anticipate that the most promising discoveries will lead to the creation of start-up companies and the building of defendable IP. Then, large pharmaceuticals will court these start-ups as they progress to become true biotechnology companies with completion of phase I, phase II clinical trials or beyond. We think that the best of these emerging biotech companies will then expand their ability to do discovery and early stage development. They will also be able to clearly evaluate and in-license additional opportunities in academia. These are exactly the skills now lacking in big pharma. These successful discovery biotech's will become the future pipelines for drugs that will go to the mid and large pharma companies centered on late development and marketing. I envision BLR Bio as becoming one of these discovery companies able to contribute significantly to filling this gap.

Want to hear more from Dr. Riser? Join him this May in Long Beach, CA for the 18th annual TIDES - Save $300 when you register using the code B16180BLOG100. Click here to register. 



Share this article with your social network, just click below to share now!


Monday, March 21, 2016

The Standardization of Single-use Components for Bioprocessing

The focus in the bioprocessing industry is shifting from acceptance of single-use technology to standardization. It is critical that components be included in the standardization discussion. The tubing connector is essential for secure, sterile, leak-free connections between various single-use systems and processes. A user can have the best filter, bag and tubing but this is all pointless if the connector is not reliable, easy-to-use or robust. Improving connector compatibility and interchangeability are great opportunities for standardization, particularly because of complications related to managing inventories.

Inventory Issues


Several inventory issues arise from lack of connector standardization:

• Increased ordering complexity because the user must define which tube set or assembly works with which part of the application. 
• Greater risks of specifying the wrong system or connection, resulting in downtime and last minute adjustments at the end user site.
• Longer lead times because systems suppliers are manufacturing lower volumes of multiple SKUs as opposed to higher volumes of fewer SKUs. This lowers the incentive and likelihood for a manufacturer to stock of these items.
• Increased stocking requirements for end users, including connectors of different genders and other components needed to create make-shift adapters.

Reducing Overhead Costs: Less is More


While overhead cost reductions might be difficult to quantify, they cannot be overlooked. Reduction in SKUs and inventory lowers the cost of managing and maintaining that inventory, which allows capital to be allocated to additional process improvements. One way to help simplify and reduce inventory is to use genderless connectors that enable transitions between tubing of different sizes. Using genderless connections (e.g. CPC’s interchangeable AseptiQuik® G connectors) eliminate the need for reducer fittings elsewhere in the process as the connectors can act as reducers.

Component Standardization


By focusing on the most versatile genderless connectors, component standardization will help bioprocessing companies make the best use of single-use technology. The right connectors will enable end users to:
• Streamline operations with easy-to-use, robust sterile connections
• Eliminate potential ordering mistakes and reduce inventory demands related to gendered connectors • Maintain more flexibility and lessen production bottlenecks with onsite connector assembly 
• Reduce overhead costs, freeing up capital for other projects

Ultimately, standardizing components by incorporating single-use genderless connectors lets end users accomplish more with fewer finished goods, saving time and money, and getting their biopharmaceutical products to market more efficiently. 


Author: Todd Andrews, Global Sales and Business Development Manager, Bioprocessing for CPC – Colder Products Company

The standardization of single-use components for bioprocessing byTodd Andrews, Colder Products Company



Share this article with your social network, just click below to share now!


Thursday, March 3, 2016

Don’t Miss BPI West!

Last chance to register for BPI West is March 9th. Use the code BPIWEST16BL and save $100- Register now!

The clock is ticking. BPI West is just over a week away! Don't miss out on networking with industry experts, scientists and executives, along with emerging and established technology companies. Your registration will gain you access to:

• 700+ global attendees
• 80+ exhibitors highlighting new products and technologies
• 65+ scientific posters showcasing novel research
• 3 thought-leading keynote presentations
• BPI West Theater Presentations
• And More!

Download the brochure for full program details.

PLUS! We're excited to announce that Michael Egholm, President of Pall Biopharmaceuticals joins the upcoming BPI West event in Oakland on March 14th! Join us as he provides an update on the Significant Technology Advances Enabling Integrated Continuous BioProcessing during Monday's The Future of Continuous Processing pre-conference symposia. Best of all, this session is complimentary to all registered attendees!



Can't make it to all 4 days? We've got you covered with special one-day Exposition Hall & Keynotes passes starting at $150! Click here for more information.


Share this article with your social network, just click below to share now!


Monday, February 22, 2016

How to Accelerate Biopharmaceutical Development and Manufacturing


At BioProcess International last October, Ganesh Vedantham, Ph.D., Director, Process and Product Engineering at Amgen moderated a panel to discuss innovation, in technology, products for acceleration of biopharmaceutical development and manufacturing. The evolution in Biopharmaceutical industry business model led by cost structure, geographic dynamics, global, economic realities and policies. And the industry trends in next 3-5 years in business model, cost structure, biopharmaceutical development and manufacturing, geographic dynamics, global realities and policies.

The panelists consisted of:
  • K.V. Subramaniam, MBA, Chief Executive Officer, Reliance Life Sciences
  • Rahul Singhvi, MBA, Chief Operating Officer, Takeda Vaccines
  • Hanne Bak, Ph.D., Senior Director, Purification Development, Regeneron Pharmaceuticals, Inc.
  • Victor Vinci, Ph.D., Chief Scientific Officer and Vice President of Process Development at Cook Pharmica
  • Gregg Nyberg, Ph.D., Director of Cell Sciences and Technologies, Amgen


Share this article with your social network, just click below to share now!


Wednesday, February 3, 2016

[Survey] Bioprocessing Efficiency | Enter for a Chance to Win









Maximize Efficiency; Streamline Biopharmaceutical Process Development & Production 

One of the major goals of BPI West it to provide information that you can use to streamline and accelerate process development and production to maximize efficiency from basic research to commercial manufacturing. With that in mind, we would greatly appreciate a few moments of your time to answer the following questions to help us better understand your needs and approaches to accomplishing these goals.


Upon completing the survey, you will be entered into a drawing to win an all-access pass* to BPI West, taking place in Oakland, CA March 14-17, 2016. Learn more about BPI West.

The compiled results of this survey will be distributed as a detailed infographic reportt, depicting the current state and future directions of the biopharmaceutical industry.

We truly value the information you have provided and thank you in advance for taking the time out of your busy day to participate in our survey.

*Offer is not valid for existing or pending registrations, and cannot be retroactively applied. IBC USA & BPI West are not responsible for any hotel or travel costs.


Share this article with your social network, just click below to share now!


Monday, February 1, 2016

[Interview] K.V. Subramaniam, Chief Executive Officer of Reliance Life Sciences

In this interview, K.V. Subramaniam, MBA, Chief Executive Officer of Reliance Life Sciences, discusses the history of Reliance Life Sciences and their companies evolution over their 13 year history. With K.V.'s extensive knowledge in emerging markets, he discusses what it takes to gain traction in India and other emerging markets... more specifically, he discusses the innovation imperatives for India and other emerging markets; in regards to where he sees needs, and the opportunities for technology and product solutions. On top of that, K.V. discusses how the market itself has changed over the years and what it will look like moving into 2016 and beyond.


Interested in learning more? Join us at BPI West - March 14-17 in Oakland, CA. Register before 2/19 with the code BPIWEST16BL and save $300!


Share this article with your social network, just click below to share now!


Wednesday, November 4, 2015

Genome Editing Applications | Brussels, Belgium | 2-3 December 2015

Get updates on Therapeutic and Biomedical Applications of CRISPRs, ZFNs, TALENs and other Genome Engineering Technologies

Genome Editing Applications 
2-3 December 2015
Sheraton Airport Hotel
Brussels, Belgium

Biomedical researchers have long strived for a reliable and efficient method of making targeted changes to the genome of living cells. With the advent of CRISPR/Cas9 researchers are now able to explore gene function in a much more thorough and cost-effective way.

This year, Lorenz Mayer from Astrazenca will be giving a presentation on their genome wide target discovery and target validation studies. Ines Royaux from Janssen Phamaceutica will also be giving a presentation touching on the team’s first experience of using genome editing for ex vivo gene therapy. Read on to find out more about what you can expect to learn from the speakers at this year's conference.

Get a sneak peek into the new developments and data the speakers will be sharing during their presentations here.

Informa's Genome Editing Applications 2015 conference, taking place on 2-3 December 2015 in Brussels, will showcase the most up-to-date therapeutic and biomedical applications emerging using CRISPRs, ZFNs, TALENs, AAVs and other genome engineering technologies. From improving lead discovery, validation of targeted cell lines and development of transgenic animal models to therapeutic uses in cell therapy & gene therapy.

This inaugural event in Europe follows the enormous success of Genome Editing Applications in March 2015 in the US from our sister company, IBC Life Sciences.

*Genome Editing Applications is co-located with Cell Therapy Manufacturing and Gene Therapy conferences with a shared exhibition area

So far, across the three conferences, over 120 have confirmed to attend with representation from biopharm, pharma and biotech companies - including Novartis Pharma AG, Glaxosmithkline, CRISPR Therapeutics, Astrazeneca, F Hoffmann-La Roche AG, GSK Pharma, Hitachi LTD, Bluebird BIO, Sanofi Pasteur, Janssen Pharmaceutica NV, Merck & CO., INC., Precision Biosciences, INC.

Hear from influential industry experts such as:

Genome Editing Applications conference in Brussels

REGISTER FOR AS LITTLE AS £799* TODAY

*Based on standard industry rate Biopharm/Pharma/Biotech 2 day conference pass for one attendee. Not including suppliers/vendors.


Share this article with your social network, just click below to share now!


Monday, October 26, 2015

"Blowing up the current paradigm": A preview of BIO Europe


By: Leah Kinthaert

On November 2, Iain Dukes, Senior Vice President of Business Development & Licensing, at Merck will be a panelist for BIO-Europe. On that day, BIO-Europe will partner with the Alliance for Regenerative Medicine (ARM) to showcase some of the most innovative companies in the cell therapy and regenerative medicine space. For a preview, you can watch Dukes at BioPharm America 2015 on a panel with others from Boehringer Ingelheim GmbH and Theraclone here. The discussion focused on how there is still a lot of unmet medical need and how Merck and others are advancing the science of immuno oncology quickly with bold investments.

PD-L1 Positivity and Response – "An emerging controversy is the importance of PD-L1 positivity with respect to response. Mercks' view is that there is a clear relationship between PD-L1 positivity and response." Said Dukes.

Data is still emerging – "When one starts looking at combination therapies, the story gets very complicated." Dukes explained. "Going away from traditional, you develop it per tumor type. Checkpoint inhibitors, other than radiation therapy, are the only treatment paradigm that works in multiple tumor types. It really blows up the current paradigm for how one explores drugs for development in cancer."

Check in on Merck – This panel is a great chance to get a follow up from Dukes on what the last few months have had in store for Merck and how they are leveraging advances in immuno-oncology. Beatrice Gerard of Quintiles will be moderating; other panelists include: Michel Detheux of iTeos, Mohamed Ragab of Bristol-Meyers Squibb and Philippe Lopes-Fernandes of Merck-Serono. This interesting mix of individuals representing big pharma and start-ups was a great discussion generator last year and promises to be very informative for both biotech start-ups looking for guidance and R&D looking to fill gaps and bring in innovation.

About Iain Dukes – Iain has more than 20 years of experience in pharmaceutical research, drug discovery, scientific and technology licensing, start-up company leadership, consultant to numerous biotech and venture capital organizations. Before joining Merck, he served as Vice President of External Research and Development at Amgen where he led the External R&D department in identifying, assessing and transacting scientific external licensing opportunities, as well as potential opportunities for academic collaborations and platform technologies. Previously, Iain was President and CEO of Essentialis Therapeutics, a small start-up company, and before that he served as Vice President, Scientific and Technology Licensing at GlaxoSmithKline, where he built a leading licensing organization. At an earlier point, he was the Head of the Ion Channel Drug Discovery Group, and later Head of Exploratory Development in Metabolic and Urogenital Diseases at GlaxoWellcome. Iain pursued initial research training at the University of Leeds, UK, and received his D.Phil. degree from the University of Oxford where he also received a B.A. in Jurisprudence. He was a post-doctoral fellow in the Department of Physiology at the University of Pennsylvania, while simultaneously completing training at Gray’s Inn, UK in anticipation of being called to the Bar.

You can see the description of the cell therapy and regenerative medicine events on November 2 and 4 here. BIO-Europe will be held in Munich, Germany.



Share this article with your social network, just click below to share now!


Thursday, October 22, 2015

Reps from Big Pharma and Start-ups Discuss Partnerships


By: Leah Kinthaert

On November 2, Mohamed Ragab, VP, Head of Oncology Search and Evaluation, Business Development, at Bristol-Meyers Squibb returns as a panelist for BIO-Europe. On that day, BIO-Europe will partner with the Alliance for Regenerative Medicine (ARM) to showcase some of the most influential and active companies in the cell therapy and regenerative medicine space. For a preview, you can watch Ragab at BIO-Europe 2014 on a panel with others from Novartis, Innovio and iTeos here. Their discussion focused on how the traditional way companies get funding for their cell therapy and regenerative medicine projects has changed; developing a product, finding a strategic partner and selling the company is no longer the norm. As one panelist said: "There is no blueprint."

Big pharma is really committed to the space – At the event last year, Ragab described what Bristol-Meyers Squibb's goals were: "We work with R&D to fill gaps, and bring in innovation from the outside. We look at early stage companies to complement what we're doing, and those at different stages of development to complement our portfolio."

Criteria for partnership should be transparent – Ragab emphasized Bristol-Meyers Squibb's commitment to transparency, saying: "We communicate (our criteria) very transparently to anyone who comes to us with an opportunity."

Check in on Bristol-Meyers Squibb – This panel is a great chance to get a follow up from Ragab on what 2015 has had in store for Bristol-Meyers Squibb and how they are leveraging advances in immuno-oncology. Beatrice Gerard of Quintiles will be moderating; other panelists include: Michel Detheux of iTeos, Iaian Dukes of MSD and Philippe Lopes-Fernandes of Merck-Serono. This interesting mix of individuals representing big pharma and start-ups was a great discussion generator last year and promises to be very informative for both biotech start-ups looking for guidance and R&D looking to fill gaps and bring in innovation.

About Mohamed Ragab – Dr. Mohamed H. Ragab is the Vice President, Search & Evaluation, Oncology and Business Development with Bristol-Myers Squibb. He received his Master Degree, Radiation Oncology and his Bachelor of Medicine and Surgery from Cairo University School of Medicine. During his 28 year career, Dr. Ragab worked previously at the National Cancer Institute in Egypt, Schering-Plough Pharmaceuticals in the Middle East, and in the United States at Ortho Biotech Products, Pfizer, Inc. and Hoffman-La Roche Inc. Dr. Ragab is on the Board of Trustees for BIO NJ.

You can see the description of the cell therapy and regenerative medicine events on November 2 and 4 here.



Share this article with your social network, just click below to share now!


Tuesday, October 20, 2015

Cell Therapy A Focus at BIO-Europe in Munich


By: Leah Kinthaert

On November 2, Michel Detheux, CEO of iTeos Therapeutics returns as a panelist for BIO-Europe in Munich. On that day, BIO-Europe will partner with the Alliance for Regenerative Medicine (ARM) to showcase some of the biggest movers and shakers in the cell therapy and regenerative medicine space. For a preview, you can watch Detheux at BIO-Europe 2014 on a panel with others from Novartis, Innovio and Bristol-Myers Squibb here. Their discussion focused on answering questions such as: "Are there opportunities to remain a company without having to exit?" and - "Is it the endgame to get acquired?"

Is it the endgame to get acquired? – At the event last year, Detheux answered this question by commenting that his company would be running out of funds the following year and that: "If a company like iTeos wants to get access to a large portfolio of different immunotherapies we need to partner quite early stage".

Partnership with Pfizer – In December 2014, iTeos partnered with Pfizer. iTeos gave Pfizer rights to their pre-clinical compounds targeting ID01 and TD02 while Pfizer was to be responsible for the development and commercialization of ID01 and TD02 drug candidates.

Check in on their partnership – Eleven months later, it will be exciting to see how the partnership between iTeos and Pfizer is moving along. Beatrice Gerard of Quintiles will be moderating; other panelists include: Mohamed Ragab, of Bristol Myers-Squibb, Iain Dukes of MSD and Philippe Lopes-Fernandes of Merck-Serono. This interesting mix of individuals representing big pharma and start-ups was a great discussion generator last year and promises to be very informative for both biotech start-ups looking for guidance and R&D looking to fill gaps and bring in innovation.

About iTeos – Based in Gosselies, Belgium, iTeos Therapeutics SA is a private biotechnology company with a focus on developing small-molecule immunomodulators for cancer treatment. Originating from a partnership between the Ludwig Institute for Cancer Research and de Duve Institute at the Université catholique de Louvain, iTeos Therapeutics SA is led by management and research teams with proven track records in tumor immunology, immunotherapy, drug discovery and development. In December 2014, iTeos signed a transformative deal with Pfizer to develop small molecules immunomodulators. In parallel with this strategic partnership, iTeos is now developing a new pipeline of proprietary programs targeting the tumor microenvironment to improve patients outcome. iTeos Therapeutics is focused on the validation and development of "immunomodulatory" molecules with the potential to act in synergy with other cancer therapies to restore immune activity against tumours. The company is interested in three enzymes involved in immunosuppression: an immunosuppressive enzyme expressed by the tumour's stromal cells. An inhibitor of this enzyme is known and its effects on humans have already been studied for other applications. iTeos hopes to begin clinical trials with this molecule by 2014; indoleamine 2,3-dioxygenase (IDO) and tryptophan 2,3-dioxygenase (TDO), for which iTeos will soon be launching a high-speed screening system for identifying inhibitory molecules. The company hopes to develop an immunomodulator from these two enzymes by 2017.

You can see the description of the cell therapy and regenerative medicine events on November 2 and 4 here.



Share this article with your social network, just click below to share now!


Tuesday, September 8, 2015

7 Bioprocess Parameters For Controlling Biopharmaceutical Glycosylation

Mammalian cells are frequently selected as expression systems for protein biopharmaceuticals because of their ability to produce proteins with ‘human-like’ post-translational modifications. The structure of these products can, to a large extent, be controlled by ensuring that the genetic sequence encoding the biopharmaceutical has been inserted stably into the host cell genome. However, the effective control of post-translational modifications such as glycosylation is much more of a challenge requiring an understanding of the cellular mechanisms that lead to different profiles along with how they can be manipulated or at least controlled by bioprocessing parameters. Yet the glycosylation profile is an important characteristic of a biopharmaceutical because of its potential to effect the biological properties of the drug such as pharmacokinetics, bioactivity and antigenicity amongst others.

Cellular Factors Impact Glycosylation

In an article entitled “Optimisationof the cellular metabolism of glycosylation for recombinant proteins producedby mammalian cell systems” (Cytotechnology, 2006, 50:57-76), Mike Butler from the University of Manitoba describes the following factors that impact glycosylation within the environment of the cell:

·         3D protein structure
·         Enzyme repertoire of the host cell
·         Transit time through Golgi apparatus
·         Availability of intracellular sugar-nucleotide donors

7 Bioprocess Parameters For Controlling Biopharmaceutical Glycosylation

Research described in Bulter’s paper has shown that engineers can utilize a range of bioprocessing parameters to effect these intracellular factors and control glycosylation profiles such as:

1. Concentration of supplements
2. Concentration of Ammonia
3. pH
4. Dissolved oxygen levels
5. Cell line selection
6. Cell growth rates
7. Protein production rate


Modelling Glycosylation Patterns

The relationship between processing parameters and recombinant protein glycosylation patterns can be determined experimentally using scale-down models and multifactorial experimental designs. However, development costs and time would be reduced still further if models capable of predicting glycol-profiles could be developed and is now a subject of investigation by researchers around the world.


Join me at #BPIconf
Contact me at nick.hutchinson@parker.com


Dr Nick Hutchinson has a Masters and Doctorate in Biochemical Engineering from University College London, UK where he focused on laboratory tools for rapid bioprocess development and characterization. He then worked at Lonza Biologics in an R&D function investigating novel methods for large-scale antibody purification before moving to an operational role scaling-up and transferring manufacturing processes between Lonza sites in the UK, Spain and USA. Nick now works in Market Development at Parker domnick hunter where his focus is in bringing Parker's strengths in Motion & Control to Bioprocessing. This will enable customers to improve the quality and deliverability of existing and future biopharmaceuticals.


Share this article with your social network, just click below to share now!


Friday, August 7, 2015

This Week in BioPharma: 8/3-8/7

Here is the top news from the biopharmaceutical industry this week:

Biotechnology is helping to heal Delaware: Nearly 22,000 women will be diagnosed with ovarian cancer this year. Another 14,000 will die from the disease. One Delaware biotech firm is working to change that. In December, Wilmington-based AstraZeneca Pharmaceuticals released Lynparza, a new medicine for women with advanced ovarian cancer. Innovative treatments like Lynparza help Delaware patients live longer and healthier lives. Drug development also keeps Delaware's economy healthy by creating jobs and supporting local businesses. But now, Congress may jeopardize the health of our state and its residents with ill-advised changes to Medicare Part D and patent laws. Read the full post here.

U.S. officials warn medical devices are vulnerable to hacking: The federal government is warning about a medical device that could be tampered with by hackers. The FDA and Department of Homeland Security issued a statement that "strongly encourages" health care facilities to discontinue the use of Hospira's Symbiq infusion pump after officials learned the devices are vulnerable to cybersecurity threats. The medical device company confirmed that the computerized pumps -- which continuously deliver medication over an extended period -- could be accessed remotely through a hospital's network. This could allow an unauthorized user to control the device and change the dosage of medication the pump delivers to a patient. Read the full post here.

Allow medical devices sector to work with doctors: Pitching for allowing medical devices industry to engage doctors, industry body CII today said preventing medical practitioners to undergo training about latest technologies may be detrimental. Currently, under the voluntary the Universal Code for Pharmaceutical marketing Practices (UCPMP) industry is not allowed to engage medical practitioners for continued medical education on latest technologies, CII said in a statement. "Medical Device Industry is an innovation driven industry and needs to work with medical practitioners as well as paramedical professional in close proximity," the industry chamber said.  Read the full post here.

How can we derisk innovation in pediatric medical devices?: Sometimes, kids need intensive medical treatment – and the tools used for adults aren’t necessarily suitable to treat smaller, growing bodies. This presents a unique challenge for surgeons and clinicians, who find themselves with limited options when treating sick children. That’s where the Sheikh Zayed Institute for Pediatric Surgical Innovation comes in. It’s a division of the Washington, D.C.-based Children’s National Health System – and focuses on making pediatric surgery more precise, less invasive and, ideally, pain-free. Kolaleh Eskandanian, executive director of the Institute, spoke with MedCity News about the unique challenges in pediatric medical device innovation – and ways they’re helping jumpstart entrepreneurship in this small but important market. Read the full post here.


Technavio Says the High Demand for Biopharmaceuticals Will Inflate the Global Single-use Bioprocessing Systems Market Through 2019:  Technavio has published a new report on the global single-use bioprocessing systems market, which is expected to grow at a CAGR of more than 34% from 2015-2019. The new report indicates the increase in the aging population is leading to a rapid increase in patient population suffering from diseases such as diabetes, hypertension, musculoskeletal and cardiovascular diseases, chronic kidney diseases, cerebral strokes, and cancer. This increases the demand for biopharmaceuticals among patients. Read the full post here.


Share this article with your social network, just click below to share now!


Monday, July 27, 2015

How to successfully integrate continuous capture with perfusion bioreactors


In a previous post I described the drivers for, and, benefits from, the trend towards the continuousproduction of biopharmaceutical drugs in which I referenced the article of Veena Warikoo from Genzyme, a Sanofi company, and co-workers published in 2012 on the “Integrated Continuous Production of RecombinantTherapeutic Proteins” (Biotech Bioeng, 2012;109: 3018-3029). Amongst Veena’s contributing authors is Konstantin Konstantinov a key contributor to the literature on continuous bioprocessing and Keynote speaker at the Bioprocess International 2015 Conference with a presentation entitled “What is the Future of Continuous Processing  – What is the Time Frame for Implementing Fully Continuous Processing in Commercial Production?"
Extending continuous processing downstream to include the capture step

A key concept that the team from Genzyme developed is the integration of continuous chromatography with a perfusion bioreactor for the production of both high volume and stable monoclonal antibodies and low volume, less stable recombinant human enzymes. A 12 L bioreactor was operated for up to 70 days by utilizing the Alternating Tangential Flow (ATF) cell retention technology. The ATF permeate that was harvest was loaded directly onto a periodic counter current (PCC) chromatography system. Systems such as these are now available from a variety of suppliers including GE Healthcare, Pall, Semba and NovaSep. Genzyme were able to operate the PCC system in a fully closed and sterile state for a prolonged period of time.


The benefits of integrating continuous culture with continuous capture
Adopting this approach can lead to significant benefits because of the high cell densities and volumetric productivities that can be achieved. This allows significantly smaller bioreactors to be used thereby reducing facility size and capital costs. The ATF system eliminated the need for a more complex harvesting system, however, integration with PCC eliminated the need for large hold tanks, a non-value adding operation, and allowed the capture column to be reduced by a minimum of two-fold.

Improved product quality of less stable proteins

Integration of upstream and downstream operations in this way allows for the continuous flow of product from the bioreactor, through the capture step and into the chromatography eluate and mitigates the risk of product degradation of less stable proteins.

Though the issue of stability may be less of a concern for monoclonal antibodies, the team have created a platform capable of delivering a range of biopharmaceuticals from within a single facility.

What is the Time Frame for Implementing Fully Continuous Processing in Commercial Production?

How would you answer this question? Do you think the industry will see this within 5 years? 10 years? 20 years? Or more?

Dr Nick Hutchinson

Join me at #BPIconf

Dr Nick Hutchinson has a Masters and Doctorate in Biochemical Engineering from University College London, UK where he focused on laboratory tools for rapid bioprocess development and characterization. He then worked at Lonza Biologics in an R&D function investigating novel methods for large-scale antibody purification before moving to an operational role scaling-up and transferring manufacturing processes between Lonza sites in the UK, Spain and USA. Nick now works in Market Development at Parker domnick hunter where his focus is in bringing Parker's strengths in Motion & Control to Bioprocessing. This will enable customers to improve the quality and deliverability of existing and future biopharmaceuticals.


Share this article with your social network, just click below to share now!


Thursday, June 18, 2015

Might the sun be setting on process-scale chromatography for the purification of biopharmaceuticals?

Browsing through the program for BPI Boston 2015 I was really excited to see Abhinav Shukla is chairing a session in the Recovery & Purification track on novel approaches to non-chromatographic purification. The session will be on Tuesday afternoon starting at 1.25pm.
Like I explained in last week’s blog the subject it’s a subject that is particularly to my heart as it’s the field I worked in as a fresh engineer in my first role upon completing my doctorate.
Bottlenecks in downstream processing
Packed-bed chromatography is, of course, the workhorse of large-scale therapeutic protein purification. The selectivity of chromatography steps especially when operated together as part of an integrated downstream purification train allows very high levels of drug purity to be achieved ensuring patient safety.
The trade-off from a method like this which has such a great ability to resolve different molecular species to give a pure product is that capacity and throughput can be compromised. This was not such an issue during the early days of the industry but as it has developed and bioreactor productivity has increased at a near exponential rate the reliance on chromatography has arguably lead to bottlenecks in purification processes.
The cost of Protein A chromatography
For some within the industry the greatest concern is around Protein A affinity chromagraphy which is an extremely common capture step for monoclonal antibodies once harvested from bioreactors. The extremely high selectivity of Protein A resin means it has a somewhat lower capacity than some alternatives and its high cost of manufacture is reflected in its cost. Though significant advances have been made in Protein A resin technology over the past 20 years there is still significant interest in finding a suitable alternative. The cost of such a consumable means it is imperative biomanufacturers must take care when using and storing the resin to maximize its lifetime.
 Novel methods for therapeutic protein purification
Elastin-like polypeptides (ELP) are fascinating biopolymers that will reversibly transition from soluble molecules to insoluble form at relatively low temperatures. A modest temperature increase will allow an ELP-tagged protein to precipitate out of solution where it can be purified from contaminants using a traditional solid-liquid separation technique such as centrifugation or hollow fibre microfiltration. Resolubilization into a desired solvent or buffer will occur when the temperature of the suspended purified protein is reduced. A great description of the method for purifying ELP-tagged proteins without recourse to chromatography is described in a publication from Ashutosh Chilkoti and others of Duke University.
Author of the 2013 article ‘Emerging Challenges to Protein A’ (BioProcess International. Oct 1, 2013) Pete Gangnon is scheduled to present at the session and hopefully will be sharing more insights into highly innovative antibody purification process he describes in the article. Gangnon highlights two techniques used in combination with one another, firstly chromatin-directed clarification followed by an approach called steric exclusion chromatography which uses polyethylene glycol and hydrophilic particle surfaces. These techniques used with a Capto Adhere chromatography step to complete the purification process gave yields of over 80% while reducing host cell protein levels to <1ppm and aggregate to <0.1%.
What is your experience?
Have you tried non-chromatographic purification methods? How successful was it? Do you think that packed-bed chromatography may have had its day?

Nick Hutchinson
Join me at #BPIconf





















Share this article with your social network, just click below to share now!


Wednesday, June 17, 2015

BPI Boston Announces its 2015 Program

By: Dr. Nick Hutchinson

Hello, welcome and thank-you for visiting our new blog aiming to provide insights and provoke discussion ahead of, and around, the Bioprocess International Conference and Exhibition which will be at Hynes Convention Center, Boston, MA  between the 26th and 29th October 2015.
Many of you will know the event of course, but for those of you who haven’t yet had the pleasure of attending this event previously, it is one of the leading bioprocessing conferences in North America and indeed attracts delegates (including myself), presenters and exhibitors from all over the globe.
If you take a moment to review the conference program you’ll see the reason why. The conference will have 6 tracks covering up- and down-stream processing, manufacturing strategies, analytical and formulation & quality, early phase biologics. This year there will be a new track on drug product manufacturing & fill-finish processing. Each session is chaired by a leader in their field who pulls together presentations addressing real industry problems that delegates can learn from and theb take this information back to their organizations to help them develop, manufacture and commercialize their biopharmaceutical products.
In addition, delegates can attend the pre-conference symposia on Monday, October 26 and will have access to the ever popular BPI Theater featuring, amongst many other things, an “Ask the Regulators” Open Forum and a Fireside Chat session focussed on the key question of how we can accelerate biopharmaceutical development and manufacturing?
There will be a Town Hall Forum Discussion addressing the crucial question of Single-Use Standardization and feature representatives from a range of industry bodies including BPOG, BPSA, PDA, ASTM and ASME/BPE.
Of course, if you need them, there are many other reasons to attend the conference such as over 150 exhibitors and over 100 posters. The opportunities to network with your industry peers are huge.
To help you prepare for the event I’ll be posting about selected topics and key themes from the conference to provide you with background and insights on the subject matter so that you can come prepared to develop collaborations and engage in discussions.
Next blog I’ll be taking a look at a subject close to my heart which is novel approaches for non-chromatographic purification processes. My first role out of college was precisely in this area in order to reduce bottlenecks in downstream processing caused by ever higher product titres being achieved upstream. I hope you’ll provide feedback and share your experiences for the benefit of other delegates.
About the Author: Dr Nick Hutchinson has a Masters and Doctorate in Biochemical Engineering from University College London, UK where he focused on laboratory tools for rapid bioprocess development and characterization. He then worked at Lonza Biologics in an R&D function investigating novel methods for large-scale antibody purification before moving to an operational role scaling-up and transferring manufacturing processes between Lonza sites in the UK, Spain and USA. Nick now works in Market Development at Parker domnick hunter where his focus is in bringing Parker's strengths in Motion & Control to Bioprocessing. This will enable customers to improve the quality and deliverability of existing and future biopharmaceuticals.
Join me at #BPIconf


Share this article with your social network, just click below to share now!


Friday, June 12, 2015

This Week in BioPharma: 6/8-6/12

Top news from the biopharmaceutical industry this week:

In the future, treatments tailored to patients: Cambridge biotechs such as Genzyme Corp. and Alnylam Pharmaceuticals Inc. are developing personalized treatments for rare genetic disorders like Gaucher and Fabry disease. Vertex Pharmaceuticals Inc. of Boston is turning out a portfolio of medicines that attack the life-threatening lung disease cystic fibrosis by targeting specific genetic mutations.

Getting to the red zone in biopharma R&D: For some time after the FDA put its new breakthrough therapy designation together for the industry, there was a good deal of back and forth among industry analysts over whether the BTD would make much of a difference. You don't hear much of that kind of carping much these days, and a new report from EP Vantage illustrates why.

Study: biopharma innovation outpaces tech overall: Innovation in the biotech and pharmaceutical industries outpaced the combined activity of 12 technology sectors between 2009 and last year, according to a report released today by Thomson Reuters.

The 25 most influential people in biopharma in 2015: A lot of people make news in the biopharma business. Few of them are influential. Influence, simply put, is the ability to make your mark in such a way as to get other prominent people in this business to rethink the way they do business.

Alder Biopharmaceuticals' new drug promises migraine relief:  Shares of clinical-stage biopharmaceutical company Alder Biopharmaceuticals Inc. are up more than 100 percent from the lows they made in late April this year and are currently trading near their all-time highs.One of the main reasons for this surge has been the promising data released by company last month for its migraine treatment drug.

Cancer clinical trials expert to assist Regen BioPharma, Inc. in addressing FDA questions: The goals  of the collaboration is to  address  questions  posed by the FDA regarding  Regn BioPharma, Inc.'s planned  Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell immunotherapy for treating breast cancer and to modify the existing Investigational New Drug application in order to maximize the probability  of clinical trial success.

Merck Millipore develops compaction technology for biopharma: Merck Millipore, the life science business of Germany-based Merck, has developed a new technology that compacts dry powder cell culture media into granules, accelerating solubility and improving flowability and handling. The compacted media are, therefore, more convenient to use, allowing biopharmaceutical manufacturers to further optimize their upstream processes.


Share this article with your social network, just click below to share now!